Clinical study of thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator for patients with acute cerebral infarction

Objective: To investigate the safety and efficacy of thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator( rt-PA) for patients with acute cerebral infarction( ACI). Methods: ACI patients within4. 5 hours of stroke onset were involved in the study. The patients were divided into rt-PA group( 61 cases) and control group( 78 cases),intravenous rt-PA or Ozagrel Sodium was received respectively. NIHSS and mRS were used to assess and compare the efficacy and safety in two groups 24 hours,7 days and 90 days after treatment. Results: The scores of NIHSS at 7 days,the mRS at 90 days in the rt-PA group were significantly better than those of control group. There were no significant statistical differences in the mortality and the incidence of symptomatic intracranial hemorrhage between the two groups. Conclusion: ACI patients who receive thrombolytic therapy with rt-PA within 4. 5 hours after disease onset achieve an effect superior to intravenous Ozagrel Sodium,and it is as safe as intravenous Ozagrel Sodium.